Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia

• Asıl Yazarlar: Tremblay G (Yazar), Dolph M (Yazar), Bhor M (Yazar), Said Q (Yazar), Roy A (Yazar), Elliott B (Yazar), Briggs A (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Dove Medical Press, 2018-11-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Gabriel Tremblay,1 Mike Dolph,1 Menaka Bhor,2 Qayyim Said,2 Anuja Roy,2 Brian Elliott,3 Andrew Briggs4 1Health Economics, Purple Squirrel Economics, New York, NY, USA; 2Health Economics and Outcomes Research, Novartis Pharmaceuticals, East Hanover, NJ, USA; 3Hematology, No...